Core Viewpoint - CG Oncology, Inc. has successfully closed a public offering of 9,200,000 shares of common stock, raising gross proceeds of $238.0 million before expenses, aimed at advancing its bladder cancer therapeutic development [1]. Group 1: Offering Details - The public offering consisted of 9,200,000 shares, with 8,500,000 shares offered by CG Oncology and 700,000 shares by an existing stockholder [1]. - The offering price was set at $28.00 per share, which included the full exercise of the underwriters' option to purchase an additional 1,200,000 shares [1]. - The gross proceeds to CG Oncology from the offering, before deducting underwriting discounts and commissions, amounted to $238.0 million [1]. Group 2: Underwriters and Management - Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, TD Cowen, and Stifel, Nicolaus & Company acted as joint book-running managers for the offering [2]. - LifeSci Capital LLC served as the lead manager for the offering [2]. Group 3: Company Overview - CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for bladder cancer patients [5]. - The company aims to enhance the quality of life for urologic cancer patients through innovative immunotherapies [5].

Group 1 - CG Oncology, Inc. (NASDAQ: CGON) reported positive results from its phase 3 BOND-003 study for the oncolytic immunotherapy candidate Cretostimogene, targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) [2] - The study's results indicate a significant advancement in treatment options for patients with NMIBC who do not respond to BCG therapy [2] - The Biotech Analysis Central service offers extensive resources for investors, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2]

Core Viewpoint - CG Oncology, Inc. has announced a public offering of 8,000,000 shares of common stock priced at $28.00 per share, aiming to raise approximately $204.4 million in gross proceeds before expenses [1]. Company Overview - CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for bladder cancer patients [5]. Offering Details - The offering consists of 7,300,000 shares offered by CG Oncology and 700,000 shares by an existing stockholder, with the offering expected to close on December 16, 2024, subject to customary closing conditions [1]. - The underwriters have a 30-day option to purchase an additional 1,200,000 shares at the public offering price [1]. - The registration statement for the offering was filed with the Securities and Exchange Commission and declared effective on December 12, 2024 [3]. Underwriters - Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, TD Cowen, and Stifel, Nicolaus & Company are acting as joint book-running managers for the offering, with LifeSci Capital LLC as the lead manager [2].

Company Overview - CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for bladder cancer patients [5]. Proposed Offering - CG Oncology has filed a registration statement on Form S-1 with the SEC for a proposed underwritten public offering of 7,300,000 shares of its common stock [1]. - An existing stockholder intends to offer and sell 700,000 shares of CG Oncology's common stock in the proposed offering [1]. - The company will not receive proceeds from the sale of shares by the selling stockholder [1]. - CG Oncology plans to grant underwriters a 30-day option to purchase up to an additional 1,200,000 shares at the public offering price, less underwriting discounts and commissions [1]. - The public offering price has not yet been determined, and the offering is subject to market and other conditions [1]. Underwriters - Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, TD Cowen, and Stifel, Nicolaus & Company are acting as joint book-running managers for the offering [2]. - LifeSci Capital LLC is serving as the lead manager for the offering [2]. Registration Statement - A registration statement relating to these securities has been filed with the SEC but has not yet become effective [3]. - The proposed offering will be made only by means of a prospectus, which will be available from the underwriters when ready [3].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-41925 CG Oncology, Inc. (Exact Name of Registrant as Specified in its Charter) De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 001-41925 37-1611499 (State or Other Jurisdiction of Incorporation)(Commission File Number) (IRS Employer Identification No.) 400 Spectrum Center Drive Suite 2040 Irvine, California 92618 (Address of Principal Executive Offices) (Zip Code) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share CGON The Nasdaq Global Select Market FORM 8-K CURRENT REPORT Pursuant ...

wildpixel Fresh from its large, $380mn IPO in January, CG Oncology (NASDAQ:CGON) achieved high success after its bladder cancer molecule cretostimogene grenadenorepvec demonstrated a 75.2% complete response at any time in 105 patients. The study was a phase 3 monotherapy study in NMIBC or high-risk non-muscle invasive bladder cancer that's unresponsive to Bacillus Calmette Guerin. This data, presented on May 3, was quickly followed on May 24 by data from a phase 2 study of the same molecule, this time in co ...

– Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature Medicine and featured at ASCO 2024 – – Announced 54% complete response (CR) rate in the intention-to-treat population at 24-month landmark and meets primary endpoint in the CORE-001 study – – Demonstrated 75.2% CR rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in Cretostimogene Monothe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Securities registered pursuant to Section 12(b) of the Act: FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ | --- | --- | |--------------------------------------- ...

Financial Results Announcement - CG Oncology, Inc. announced its financial results for the quarter ended June 30, 2024 [6] - The press release detailing the financial results was issued on August 8, 2024 [6] - The press release is attached as Exhibit 99.1 and incorporated by reference [6] Regulatory and Compliance Information - The information in the Form 8-K, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act [7] - The report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 [5] - The report was signed by Josh Patterson, General Counsel and Chief Compliance Officer of CG Oncology, Inc. [10] Company Classification and Market Information - CG Oncology, Inc. is classified as an emerging growth company [6] - CG Oncology, Inc. is registered on the Nasdaq Global Select Market under the trading symbol CGON [4] Company Contact Information - The company's principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, California 92618 [2] - The company's telephone number is (949) 409-3700 [5]